DRAGONFLY-AI
12.4.2022 13:21:05 CEST | Business Wire | Press release
Dragonfly AI, the market leading predictive visual analytics platform, announced today that it has closed a £3m Series A funding round led by Guinness Ventures and existing investors Downing Ventures , while Capita PLC also participated in the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005628/en/
Dragonfly AI has seen rapid growth in its customer portfolio which includes over 50 global brands including Diageo, GSK, and Vodafone. The new investment allows Dragonfly AI to further scale up its sales engine, build the client growth team and invest in an exciting behavioural science, R&D and product development roadmap. The funds will also be used to accelerate international expansion plans across Europe and North America.
Co-founded in 2018, by entrepreneurs Mark Bainbridge and David Mitchell, Dragonfly AI helps brands improve creative performance by accurately and instantly predicting what your audience sees first across any content, any channel.
Using the power of artificial intelligence and cutting-edge neuroscience technology, the easy -to-use technology provides real-time actionable insights, that helps marketers and insight teams make data-informed decisions, resulting in better informed creative decisions, performance marketing and improved sales performance.
Richard Mann, Chief Executive Officer at Dragonfly AI said: “We’re delighted to close this round of funding from investors that share our vision for the value that predictive technologies can bring to the creative design process. The investment will allow Dragonfly AI to continue scaling-up across Europe and the US. It will also allow us to invest more heavily in our technology platform, including initiatives such as the new e-commerce benchmarks that we are launching this quarter.”
Shane Gallwey, Head of Guinness Ventures said: “Dragonfly’s predictive visual tools are best in class, which is why leading global brands already use the technology to optimise their marketing. Our investment into Dragonfly brings another gem to the Guinness portfolio and we look forward to supporting their success as they scale-up their business.”
Richard Lewis, Partner at Downing Ventures said: “We are thrilled to be supporting Dragonfly in the next stage of its growth journey. It is a privilege to continue to support entrepreneurial teams that have developed world-class, innovative technology here at Downing. We look forward to continuing the good work with Dragonfly and assisting with its international expansion.”
Matt Bunn, Co-Founder and Managing Director at Capita Scaling Partner, added: “This represents a fantastic milestone for Dragonfly, and we are delighted to continue our support for the business. The company is on an exciting growth trajectory and continues to develop its world-leading product. We are looking forward to working closely with Guinness, Downing and the Dragonfly team to further expand its international client base.”
*Press Release Ends*
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005628/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release
Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release
Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 13:30:00 CEST | Press release
Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed. Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® meth
Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 12:00:00 CEST | Press release
Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTSGross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom